Leonid Beigelman
Overview
Explore the profile of Leonid Beigelman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
420
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Debing Y, Vanrusselt H, Degrauwe L, Silva de Oliveira D, Kariuki C, Ebwanga E, et al.
Antiviral Res
. 2024 Feb;
224:105835.
PMID: 38401714
Nucleic acid polymers (NAPs) are an attractive treatment modality for chronic hepatitis B (CHB), with REP2139 and REP2165 having shown efficacy in CHB patients. A subset of patients achieve functional...
2.
Jekle A, Thatikonda S, Jaisinghani R, Ren S, Kinkade A, Stevens S, et al.
Int J Mol Sci
. 2023 Nov;
24(22).
PMID: 38003463
Stimulator of interferon genes (STING) agonists have shown potent anti-tumor efficacy in various mouse tumor models and have the potential to overcome resistance to immune checkpoint inhibitors (ICI) by linking...
3.
Vanrusselt H, Kum D, Taverniti V, Liu C, Sanchez A, Corthout N, et al.
J Virol
. 2023 Sep;
97(10):e0072223.
PMID: 37754761
Chronic hepatitis B is the most important cause of liver cancer worldwide and affects more than 290 million people. Current treatments are mostly suppressive and rarely lead to a cure....
4.
Martinez-Montero S, Rajwanshi V, Pandey R, De Costa N, Hong J, Beigelman L, et al.
Nucleic Acid Ther
. 2023 Aug;
33(5):319-328.
PMID: 37638793
We describe here the design, synthesis, physicochemical properties, and hepatitis B antiviral activity of new 2'-O-alkyl ribonucleotide N3'→P5' phosphoramidate (2'-O-alkyl-NPO) and (thio)-phosphoramidite (2'--alkyl-NPS) oligonucleotide analogs. Oligonucleotides with different 2'-O-alkyl modifications...
5.
Kum D, Vanrusselt H, Sanchez A, Taverniti V, Verrier E, Baumert T, et al.
Hepatology
. 2023 Apr;
78(4):1252-1265.
PMID: 37102495
Background And Aims: Effective therapies leading to a functional cure for chronic hepatitis B are still lacking. Class A capsid assembly modulators (CAM-As) are an attractive modality to address this...
6.
Jochmans D, Liu C, Donckers K, Stoycheva A, Boland S, Stevens S, et al.
mBio
. 2023 Jan;
14(1):e0281522.
PMID: 36625640
The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors to select...
7.
Ushach I, Zhu R, Rosler E, Pandey R, De Costa N, Pourshahian S, et al.
Mol Ther Nucleic Acids
. 2022 Mar;
27:1103-1115.
PMID: 35228903
Despite the existence of a prophylactic vaccine against hepatitis B virus (HBV), chronic hepatitis B virus (CHB) infection remains the leading cause of cirrhosis and liver cancer in developing countries....
8.
Kao C, Nie Y, Ren S, De Costa N, Pandey R, Hong J, et al.
Mol Ther Nucleic Acids
. 2022 Jan;
27:335-348.
PMID: 35024245
A functional cure of chronic hepatitis B requires eliminating the hepatitis B virus (HBV)-encoded surface antigen (HBsAg), which can suppress immune responses. STOPS are phosphorothioated single-stranded oligonucleotides containing novel chemistries...
9.
Vandyck K, Abdelnabi R, Gupta K, Jochmans D, Jekle A, Deval J, et al.
Biochem Biophys Res Commun
. 2021 Apr;
555:134-139.
PMID: 33813272
There is an urgent need for antivirals targeting the SARS-CoV-2 virus to fight the current COVID-19 pandemic. The SARS-CoV-2 main protease (3CLpro) represents a promising target for antiviral therapy. The...
10.
Liu C, Boland S, Scholle M, Bardiot D, Marchand A, Chaltin P, et al.
Antiviral Res
. 2021 Jan;
187:105020.
PMID: 33515606
The 3-chymotrypsin-like cysteine protease (3CLpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered a major target for the discovery of direct antiviral agents. We previously reported the evaluation...